As the mR­NA push con­tin­ues, Sam­sung will ex­pand its drug sub­stance man­u­fac­tur­ing at South Ko­re­an hub

As the de­mand for mR­NA ca­pac­i­ty grows, Sam­sung Bi­o­log­ics has an­nounced the ad­di­tion of drug sub­stance pro­duc­tion ca­pa­bil­i­ty to its fa­cil­i­ties by the first half of 2022, in an ef­fort to en­sure end-to-end mR­NA vac­cine man­u­fac­tur­ing at an ex­ist­ing South Ko­rea plant.

The move is part of the com­pa­ny’s longterm strat­e­gy as it’s been ex­pand­ing its port­fo­lio and ca­pac­i­ty to meet the rapid­ly ris­ing mar­ket de­mand be­yond its cur­rent busi­ness fo­cused on mon­o­clon­al an­ti­bod­ies. This move will com­ple­ment the con­struc­tion of its fourth — and largest — man­u­fac­tur­ing site in In­cheon, South Ko­rea.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER